Showing results (81-90 of 98) with videos related to

Sort By:
Pageof 10
American Journal of Cancer Research|October 18, 2021
Assessment of TMB, PD-L1, and lymphocyte to monocyte ratio as predictive potential in a phase Ib study of sintilimab in patients with advanced solid tumorsHaiping Jiang, Ning Li, Huan Wang, et al.
National Science Review|October 3, 2025
Cell-GraphCompass: modeling single cells with graph structure foundation modelChen Fang, Wentao Cui, Zhilong Hu, et al.
Clinical and Translational Science|November 29, 2024
Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplificationJiajia Yuan, Lin Shen, Tian Shu Liu, et al.
Journal for Immunotherapy of Cancer|March 17, 2022
Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 studyHaiping Jiang, Xiongfei Yu, Ning Li, et al.
Annals of Surgical Oncology|June 27, 2026
A Prospective Multicenter Comparative Cohort Study of Neoadjuvant Sintilimab Plus Chemotherapy and Chemoradiotherapy in Resectable Clinical Node-Positive Esophageal Squamous Cell CarcinomaAizemaiti Rusidanmu, Kun Zhou, Xingxin Zhu, et al.
Nature Biomedical Engineering|April 16, 2021
Enhanced tumour penetration and prolonged circulation in blood of polyzwitterion-drug conjugates with cell-membrane affinitySiqin Chen, Yin Zhong, Wufa Fan, et al.
Frontiers in Oncology|June 2, 2022
RRM2 Mediates the Anti-Tumor Effect of the Natural Product Pectolinarigenin on Glioblastoma Through Promoting CDK1 Protein Degradation by Increasing Autophagic FluxHaiping Jiang, Dongzhi Zhang, Karpov Denis Aleksandrovich, et al.
Cancer Letters|April 13, 2019
IL1RN mediates the suppressive effect of methionine deprivation on glioma proliferationKaikai Wang, Huailei Liu, Jiaqi Liu, et al.
BMC Medicine|October 25, 2022
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trialDan Liu, Jun Zhou, Yongsheng Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 11, 2024
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumorsJian Li, Ye Xu, Aimin Zang, et al.
Pageof 10